These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 7628177)

  • 1. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective.
    Bakke OM; Manocchia M; de Abajo F; Kaitin KI; Lasagna L
    Clin Pharmacol Ther; 1995 Jul; 58(1):108-17. PubMed ID: 7628177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety.
    Bakke OM; Wardell WM; Lasagna L
    Clin Pharmacol Ther; 1984 May; 35(5):559-67. PubMed ID: 6713769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
    Rawson NS
    CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009.
    Qureshi ZP; Seoane-Vazquez E; Rodriguez-Monguio R; Stevenson KB; Szeinbach SL
    Pharmacoepidemiol Drug Saf; 2011 Jul; 20(7):772-7. PubMed ID: 21574210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drug approval times and safety warnings in the United States and Canada, 1992-2011.
    Rawson NS
    J Popul Ther Clin Pharmacol; 2013; 20(2):e67-81. PubMed ID: 23650206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety-related regulatory actions for biologicals approved in the United States and the European Union.
    Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Schellekens H; Leufkens HG; Egberts AC
    JAMA; 2008 Oct; 300(16):1887-96. PubMed ID: 18940975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New drug approval times and 'therapeutic potential' in Canada, Australia, Sweden and the United States during the period 1992 to 1998.
    Rawson NS; Kaitin KI
    Can J Clin Pharmacol; 2000; 7(2):97-101. PubMed ID: 10958705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
    Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
    PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timeliness of review and approval of new drugs in Canada from 1999 through 2001: is progress being made?
    Rawson NS
    Clin Ther; 2003 Apr; 25(4):1230-47. PubMed ID: 12809970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-review deadlines and safety problems.
    Carpenter D; Zucker EJ; Avorn J
    N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symposium on drug safety. The role of regulatory agencies and industry in assessment of the safety of drugs for use in man. The situation in the United Kingdom.
    Cahal DA
    Can Med Assoc J; 1968 Feb; 98(6):271-5. PubMed ID: 5636096
    [No Abstract]   [Full Text] [Related]  

  • 14. Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009.
    Outterson K; Powers JH; Seoane-Vazquez E; Rodriguez-Monguio R; Kesselheim AS
    J Law Med Ethics; 2013; 41(3):688-96. PubMed ID: 24088160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs.
    Roth-Cline MD
    Circulation; 2006 May; 113(18):2253-9. PubMed ID: 16684875
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of the safety of several nonsteroidal anti-inflammatory drugs currently or formerly marketed in the United Kingdom.
    Speirs CJ
    J Clin Pharmacol; 1988 Dec; 28(s1):S8-12. PubMed ID: 3243936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985).
    Prentis RA; Lis Y; Walker SR
    Br J Clin Pharmacol; 1988 Mar; 25(3):387-96. PubMed ID: 3358900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.
    Frank C; Himmelstein DU; Woolhandler S; Bor DH; Wolfe SM; Heymann O; Zallman L; Lasser KE
    Health Aff (Millwood); 2014 Aug; 33(8):1453-9. PubMed ID: 25092848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WITHDRAWN--a resource for withdrawn and discontinued drugs.
    Siramshetty VB; Nickel J; Omieczynski C; Gohlke BO; Drwal MN; Preissner R
    Nucleic Acids Res; 2016 Jan; 44(D1):D1080-6. PubMed ID: 26553801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.